Top

Current Geriatrics Reports

Published in:

01-12-2020 | Insulins | Nutrition, Obesity, and Diabetes (SML Ribeiro, Section Editor)

Diet, Microbioma, and Diabetes in Aging

Authors: Shirley Steffany Muñoz Fernandez, Sandra Maria Lima Ribeiro

Published in: Current Geriatrics Reports | Issue 4/2020

Abstract

Purpose of Review

To describe the relationships between gut microbiota (GM), metabolism, immune system, and the association with the development of type-2 diabetes mellitus (T2DM); to gather up to date researches investigating the role of diet in the prevention and management of T2DM, in particular in older ages.

Recent Findings

An overwhelming number of microbes colonize the human body, and most of them reside in the gut. The appropriate integration between the gut environment components, the host metabolism, and the host immune system is considered a key marker of health. Changes in the balance between these components, basically defined as dysbiosis, can trigger, therefore, metabolic and immune responses, leading to systemic inflammation. These changes are associated with insulin resistance in different body tissues, playing critical roles in the induction and progression of T2DM. Different nutritional interventions have shown promising modulation in gut microbiota, for instance, pre-, pro-, and synbiotics, as well as high-fiber foods, such as fruits and vegetables. Dietary patterns considered to be anti-inflammatory, such as the Mediterranean, have shown critical modulatory effects.

Summary

Despite the fascinating findings regarding the role of GM in the host’s metabolism and immunity, there are still lacks in the knowledge about the best strategies to modulate the GM and improvement of health.

Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–14. https://doi.org/10.1038/nature11234.CrossRef

Costa M, Weese JS. Methods and basic concepts for microbiota assessment. Vet J. 2019;249:10–5. https://doi.org/10.1016/j.tvjl.2019.05.005.CrossRefPubMed

Macfarlane S, Dillon JF. Microbial biofilms in the human gastrointestinal tract. J Appl Microbiol. 2007;102:1187–96. https://doi.org/10.1111/j.1365-2672.2007.03287.x.CrossRefPubMed

Ticinesi A, Nouvenne A, Tana C, Prati B, Cerundolo N, Miraglia C, et al. The impact of intestinal microbiota on bio-medical research: definitions, techniques and physiology of a “new frontier”. Acta Biomed. 2018;89:52–9. https://doi.org/10.23750/abm.v89i9-S.7906.CrossRefPubMed

Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14:685–90. https://doi.org/10.1038/ni.2608.CrossRefPubMedPubMedCentral

• Quigley EMM. Basic definitions and concepts: organization of the gut microbiome. Gastroenterol Clin N Am. 2017;46:1–8. https://doi.org/10.1016/j.gtc.2016.09.002Fundamental concepts on gut microbiome.CrossRef

Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int. 2017;66:515–22. https://doi.org/10.1016/j.alit.2017.07.010.CrossRefPubMed

Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–80. https://doi.org/10.1038/nature09944.CrossRefPubMedPubMedCentral

Nuriel-Ohayon M, Neuman H, Koren O. Microbial changes during pregnancy, birth, and infancy. Front Microbiol. 2016;7:1031. https://doi.org/10.3389/fmicb.2016.01031.CrossRefPubMedPubMedCentral

10.

•• Ticinesi A, Tana C, Nouvenne A. The intestinal microbiome and its relevance for functionality in older persons. Curr Opin Clin Nutr Metab Care. 2019;22:4–12. https://doi.org/10.1097/MCO.0000000000000521 Important discussion about the role of gut microbiome in aging.CrossRefPubMed

11.

Zapata HJ, Quagliarello VJ. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc. 2015;63:776–81. https://doi.org/10.1111/jgs.13310.CrossRefPubMedPubMedCentral

12.

Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488:178–84. https://doi.org/10.1038/nature11319.CrossRefPubMed

13.

Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489:231–41. https://doi.org/10.1038/nature11551.CrossRefPubMedPubMedCentral

14.

Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15:1546–58. https://doi.org/10.2174/138161209788168164.CrossRefPubMed

15.

Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185:3190–8. https://doi.org/10.4049/jimmunol.0903670.CrossRefPubMed

16.

Wang G, Huang S, Wang Y, Cai S, Yu H, Liu H, et al. Bridging intestinal immunity and gut microbiota by metabolites. Cell Mol Life Sci. 2019;76:3917–37. https://doi.org/10.1007/s00018-019-03190-6.CrossRefPubMedPubMedCentral

17.

Leeming ER, Johnson AJ, Spector TD, Le Roy CI. Effect of diet on the gut microbiota: rethinking intervention duration. Nutrients. 2019;11:2862. https://doi.org/10.3390/nu11122862.CrossRefPubMedCentral

18.

Flint HJ, Duncan SH, Scott KP, Louis P. Links between diet, gut microbiota composition and gut metabolism. Proc Nutr Soc. 2015;74:13–22. https://doi.org/10.1017/S0029665114001463.CrossRefPubMed

19.

Levy M, Blacher E, Elinav E. Microbiome, metabolites and host immunity. Curr Opin Microbiol. 2017;35:8–15. https://doi.org/10.1016/j.mib.2016.10.003.CrossRefPubMed

20.

Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunger MK, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011;13:517–26. https://doi.org/10.1016/j.cmet.2011.02.018.CrossRefPubMedPubMedCentral

21.

Kaiko GE, Ryu SH, Koues OI, Collins PL, Solnica-Krezel L, Pearce EJ, et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell. 2016;165:1708–20. https://doi.org/10.1016/j.cell.2016.05.018.CrossRefPubMedPubMedCentral

22.

Ghorbani P, Santhakumar P, Hu Q, Djiadeu P, Wolever TMS, Palaniyar N, et al. Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. Eur Respir J. 2015;46:1033–45. https://doi.org/10.1183/09031936.00143614.CrossRefPubMed

23.

Lu VB, Gribble FM, Reimann F. Free fatty acid receptors in enteroendocrine cells. Endocrinology. 2018;159:2826–35. https://doi.org/10.1210/en.2018-00261.CrossRefPubMed

24.

Priyadarshini M, Cole C, Oroskar G, Ludvik AE, Wicksteed B, He C, et al. Free fatty acid receptor 3 differentially contributes to β-cell compensation under high-fat diet and streptozotocin stress. Am J Phys Regul Integr Comp Phys. 2020;318:R691–700. https://doi.org/10.1152/ajpregu.00128.2019.CrossRef

25.

Li G, Young KD. Indole production by the tryptophanase TnaA in Escherichia coli is determined by the amount of exogenous tryptophan. Microbiology. 2013;159:402–10. https://doi.org/10.1099/mic.0.064139-0.CrossRefPubMed

26.

Whitehead TR, Price NP, Drake HL, Cotta MA. Catabolic pathway for the production of skatole and indoleacetic acid by the acetogen Clostridium drakei, Clostridium scatologenes, and swine manure. Appl Environ Microbiol. 2008;74:1950–3. https://doi.org/10.1128/AEM.02458-07.CrossRefPubMedPubMedCentral

27.

Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39:372–85. https://doi.org/10.1016/j.immuni.2013.08.003.CrossRefPubMed

28.

Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47:241–59. https://doi.org/10.1194/jlr.R500013-JLR200.CrossRefPubMed

29.

Turroni S, Brigidi P, Cavalli A, Candela M. Microbiota-host transgenomic metabolism, bioactive molecules from the inside. J Med Chem. 2018;61:47–61. https://doi.org/10.1021/acs.jmedchem.7b00244.CrossRefPubMed

30.

Levy M, Thaiss CA, Zeevi D, Dohnalová L, Zilberman-Schapira G, Mahdi JA, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell. 2015;163:1428–43. https://doi.org/10.1016/j.cell.2015.10.048.CrossRefPubMedPubMedCentral

31.

Berndt BE, Zhang M, Owyang SY, Cole TS, Wang TW, Luther J, et al. Butyrate increases IL-23 production by stimulated dendritic cells. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1384–92. https://doi.org/10.1152/ajpgi.00540.2011.CrossRefPubMedPubMedCentral

32.

Masaki T, Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol Sci. 2006;27:279–84. https://doi.org/10.1016/j.tips.2006.03.008.CrossRefPubMed

33.

Millard AL, Mertes PM, Ittelet D, Villard F, Jeannesson P, Bernard J. Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages. Clin Exp Immunol. 2002;130:245–55. https://doi.org/10.1046/j.0009-9104.2002.01977.x.CrossRefPubMedPubMedCentral

34.

Vinolo MAR, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. 2011;22:849–55. https://doi.org/10.1016/j.jnutbio.2010.07.009.CrossRefPubMed

35.

Capodici C, Hanft S, Feoktistov M, Pillinger MH. Phosphatidylinositol 3-kinase mediates chemoattractant-stimulated, CD11b/CD18-dependent cell-cell adhesion of human neutrophils: evidence for an ERK-independent pathway. J Immunol. 1998;160:1901 LP–909.

36.

Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR–S6K pathway. Mucosal Immunol. 2015;8:80–93. https://doi.org/10.1038/mi.2014.44.CrossRefPubMed

37.

Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–73. https://doi.org/10.1126/science.1241165.CrossRefPubMed

38.

Kim M, Qie Y, Park J, Kim CH. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe. 2016;20:202–14. https://doi.org/10.1016/j.chom.2016.07.001.CrossRefPubMedPubMedCentral

39.

Peterson DA, McNulty NP, Guruge JL, Gordon JI. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe. 2007;2:328–39. https://doi.org/10.1016/j.chom.2007.09.013.CrossRefPubMed

40.

Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535:65–74. https://doi.org/10.1038/nature18847.CrossRefPubMed

41.

Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014;514:237–41. https://doi.org/10.1038/nature13564.CrossRefPubMed

42.

Sonnenberg GF, Artis D. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med. 2015;21:698–708. https://doi.org/10.1038/nm.3892.CrossRefPubMedPubMedCentral

43.

Kruglov AA, Grivennikov SI, Kuprash DV, Winsauer C, Prepens S, Seleznik GM, et al. Nonredundant function of soluble LTα3 produced by innate lymphoid cells in intestinal homeostasis. Science. 2013;342:1243–6. https://doi.org/10.1126/science.1243364.CrossRefPubMed

44.

Goto Y, Obata T, Kunisawa J, Sato S, Ivanov II, Lamichhane A, et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science (80- ). 2014;345:1254009. https://doi.org/10.1126/science.1254009.CrossRef

45.

Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H, et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature. 2017;551:585–9. https://doi.org/10.1038/nature24628.CrossRefPubMedPubMedCentral

46.

O’Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32–48. https://doi.org/10.1016/j.bbr.2014.07.027.CrossRefPubMed

47.

Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3:543–53. https://doi.org/10.1016/s1097-2765(00)80348-2.CrossRefPubMed

48.

Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103:3920–5. https://doi.org/10.1073/pnas.0509592103.CrossRefPubMedPubMedCentral

49.

Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183:6251–61. https://doi.org/10.4049/jimmunol.0803978.CrossRefPubMed

50.

Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol. 2017;18:2. https://doi.org/10.1186/s12865-016-0187-3.CrossRefPubMedPubMedCentral

51.

Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science. 2000;289:1560–3. https://doi.org/10.1126/science.289.5484.1560.CrossRefPubMed

52.

Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AGP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004;5:104–12. https://doi.org/10.1038/ni1018.CrossRefPubMed

53.

Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature. 2012;482:395–9. https://doi.org/10.1038/nature10772.CrossRefPubMedPubMedCentral

54.

Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, et al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332:974–7. https://doi.org/10.1126/science.1206095.CrossRefPubMedPubMedCentral

55.

Franchi L, Kamada N, Nakamura Y, Burberry A, Kuffa P, Suzuki S, et al. NLRC4-driven production of IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol. 2012;13:449–56. https://doi.org/10.1038/ni.2263.CrossRefPubMedPubMedCentral

56.

Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317:256–60. https://doi.org/10.1126/science.1145697.CrossRefPubMed

57.

Tsuji M, Komatsu N, Kawamoto S, Suzuki K, Kanagawa O, Honjo T, et al. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer’s patches. Science. 2009;323:1488–92. https://doi.org/10.1126/science.1169152.CrossRefPubMed

58.

Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol. 2009;9:883–9. https://doi.org/10.1038/nri2660.CrossRefPubMed

59.

Cong Y, Feng T, Fujihashi K, Schoeb TR, Elson CO. A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci U S A. 2009;106:19256–61. https://doi.org/10.1073/pnas.0812681106.CrossRefPubMedPubMedCentral

60.

He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;26:812–26. https://doi.org/10.1016/j.immuni.2007.04.014.CrossRefPubMed

61.

Kaetzel CS. Cooperativity among secretory IgA, the polymeric immunoglobulin receptor, and the gut microbiota promotes host–microbial mutualism. Immunol Lett. 2014;162:10–21. https://doi.org/10.1016/j.imlet.2014.05.008.CrossRefPubMedPubMedCentral

62.

Mathias A, Pais B, Favre L, Benyacoub J, Corthésy B. Role of secretory IgA in the mucosal sensing of commensal bacteria. Gut Microbes. 2014;5:688–95. https://doi.org/10.4161/19490976.2014.983763.CrossRefPubMedPubMedCentral

63.

Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14:282–9. https://doi.org/10.1038/nm1720.CrossRefPubMed

64.

Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate immune system. Curr Opin Immunol. 2010;22:507–13. https://doi.org/10.1016/j.coi.2010.05.003.CrossRefPubMedPubMedCentral

65.

Kalupahana NS, Moustaid-Moussa N, Claycombe KJ. Immunity as a link between obesity and insulin resistance. Mol Asp Med. 2012;33:26–34. https://doi.org/10.1016/j.mam.2011.10.011.CrossRef

66.

Yang J, Park Y, Zhang H, Xu X, Laine GA, Dellsperger KC, et al. Feed-forward signaling of TNF-α and NF-κB via IKK-β pathway contributes to insulin resistance and coronary arteriolar dysfunction in type 2 diabetic mice. Am J Physiol Circ Physiol. 2009;296:H1850–8. https://doi.org/10.1152/ajpheart.01199.2008.CrossRef

67.

Caricilli A, Saad M. The role of gut microbiota on insulin resistance. Nutrients. 2013;5:829–51. https://doi.org/10.3390/nu5030829.CrossRefPubMedPubMedCentral

68.

Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, et al. Liver steatosis, gut-liver axis, microbiome and environmental factors. A never-ending bidirectional cross-talk. J Clin Med. 2020;9:2648. https://doi.org/10.3390/jcm9082648.CrossRefPubMedCentral

69.

McPhee JB, Schertzer JD. Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation. Clin Sci. 2015;129:1083–96. https://doi.org/10.1042/CS20150431.CrossRef

70.

Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019;129:3990–4000. https://doi.org/10.1172/JCI129187.CrossRefPubMedPubMedCentral

71.

Vila IK, Badin P-M, Marques M-A, Monbrun L, Lefort C, Mir L, et al. Immune cell toll-like receptor 4 mediates the development of obesity- and endotoxemia-associated adipose tissue fibrosis. Cell Rep. 2014;7:1116–29. https://doi.org/10.1016/j.celrep.2014.03.062.CrossRefPubMed

72.

•• Mandaliya DK, Seshadri S. Short chain fatty acids, pancreatic dysfunction and type 2 diabetes. Pancreatology. 2019;19:280–4. https://doi.org/10.1016/j.pan.2019.01.021Importance of the GM metabolites in the development of T2DM.CrossRefPubMed

73.

•• Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol 2020:11. https://doi.org/10.3389/fimmu.2020.01582. Two-way relationship between T2DM and GM.

74.

Jayashree B, Bibin YS, Prabhu D, Shanthirani CS, Gokulakrishnan K, Lakshmi BS, et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem. 2014;388:203–10. https://doi.org/10.1007/s11010-013-1911-4.CrossRefPubMed

75.

Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr. 2013;97:505–16. https://doi.org/10.3945/ajcn.112.042457.CrossRefPubMed

76.

David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–63.CrossRefPubMed

77.

Xiao S, Fei N, Pang X, Shen J, Wang L, Zhang B, et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. 2014;87:357–67. https://doi.org/10.1111/1574-6941.12228.CrossRefPubMed

78.

Garcia-Mantrana I, Selma-Royo M, Alcantara C, Collado MC. Shifts on gut microbiota associated to Mediterranean diet adherence and specific dietary intakes on general adult population. Front Microbiol. 2018;9:890. https://doi.org/10.3389/fmicb.2018.00890.CrossRefPubMedPubMedCentral

79.

Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. Bereswill S, editor. PLoS One 2010:5:e9085. https://doi.org/10.1371/journal.pone.0009085.

80.

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. https://doi.org/10.1038/nature11450.CrossRefPubMed

81.

Delzenne NM, Cani PD, Everard A, Neyrinck AM, Bindels LB. Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia. 2015;58:2206–17. https://doi.org/10.1007/s00125-015-3712-7.CrossRefPubMed

82.

Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012;4:1095–119. https://doi.org/10.3390/nu4081095.CrossRefPubMedPubMedCentral

83.

•• Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science (80- ). 2018;359:1151–6. https://doi.org/10.1126/science.aao5774Nutritional associations between GM and T2DM.CrossRef

84.

Candela M, Biagi E, Soverini M, Consolandi C, Quercia S, Severgnini M, et al. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-Pi 2 diet. Br J Nutr. 2016;116:80–93. https://doi.org/10.1017/S0007114516001045.CrossRefPubMedPubMedCentral

85.

Kim M-S, Hwang S-S, Park E-J, Bae J-W. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 2013:n/a-n/a. https://doi.org/10.1111/1758-2229.12079.

86.

Haro C, Montes-Borrego M, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, et al. Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. J Clin Endocrinol Metab. 2016;101:233–42. https://doi.org/10.1210/jc.2015-3351.CrossRefPubMed

87.

•• Medina-Vera I, Sanchez-Tapia M, Noriega-López L, Granados-Portillo O, Guevara-Cruz M, Flores-López A, et al. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes Metab. 2019;45:122–31. https://doi.org/10.1016/j.diabet.2018.09.004Nutritional associations between GM and T2DM.CrossRefPubMed

88.

Balfegó M, Canivell S, Hanzu FA, Sala-Vila A, Martínez-Medina M, Murillo S, et al. Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial. Lipids Health Dis. 2016;15:78. https://doi.org/10.1186/s12944-016-0245-0.CrossRefPubMedPubMedCentral

89.

•• Eriksen AK, Brunius C, Mazidi M, Hellström PM, Risérus U, Iversen KN, et al. Effects of whole-grain wheat, rye, and lignan supplementation on cardiometabolic risk factors in men with metabolic syndrome: a randomized crossover trial. Am J Clin Nutr. 2020;111:864–76. https://doi.org/10.1093/ajcn/nqaa026Nutritional associations between GM and T2DM.CrossRefPubMed

90.

Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079–94. https://doi.org/10.1016/j.cell.2015.11.001.CrossRefPubMed

91.

Stenman LK, Burcelin R, Lahtinen S. Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans–towards treatment with probiotics. Benefic Microbes. 2016;7:11–22. https://doi.org/10.3920/BM2015.0069.CrossRef

92.

•• Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25:1096–103. https://doi.org/10.1038/s41591-019-0495-2Nutritional associations between GM and T2DM.CrossRefPubMedPubMedCentral

93.

•• Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RMG, Møller K, Svendsen KD, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010;104:1831–8. https://doi.org/10.1017/S0007114510002874Nutritional associations between GM and T2DM.CrossRefPubMed

94.

•• Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak M-Y. Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. Eur J Nutr. 2017;56:1535–50. https://doi.org/10.1007/s00394-016-1199-8Nutritional associations between GM and T2DM.CrossRefPubMed

95.

•• Tonucci LB, Olbrich dos Santos KM, Licursi de Oliveira L, Rocha Ribeiro SM, Duarte Martino HS. Clinical application of probiotics in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Clin Nutr. 2017;36:85–92. https://doi.org/10.1016/j.clnu.2015.11.011Nutritional associations between GM and T2DM.CrossRefPubMed

96.

Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: a randomised controlled study. Sci Rep. 2017;7:12115. https://doi.org/10.1038/s41598-017-12535-9.CrossRefPubMedPubMedCentral

97.

Khalili L, Alipour B, Asghari Jafar-Abadi M, Faraji I, Hassanalilou T, Mesgari Abbasi M, et al. The effects of Lactobacillus casei on glycemic response, serum sirtuin1 and fetuin-a levels in patients with type 2 diabetes mellitus: a randomized controlled trial. Iran Biomed J. 2019;23:68–77. https://doi.org/10.29252/.23.1.68.CrossRefPubMedPubMedCentral

98.

Mobini R, Tremaroli V, Ståhlman M, Karlsson F, Levin M, Ljungberg M, et al. Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2017;19:579–89. https://doi.org/10.1111/dom.12861.CrossRefPubMed

99.

Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012;28:539–43. https://doi.org/10.1016/j.nut.2011.08.013.CrossRefPubMed

100.

Judiono J, Hadisaputro S, Indranila KS, Cahyono B, Suzery M, Widiastuti Y, et al. Effects of clear kefir on biomolecular aspects of glycemic status of type 2 diabetes mellitus (T2DM) patients in Bandung, West Java [Study on Human Blood Glucose, c Peptide and Insulin]. Funct Foods Health Dis. 2014;4:340. https://doi.org/10.31989/ffhd.v4i8.145.CrossRef

101.

Moroti C, Souza Magri L, de Rezende CM, Cavallini DC, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012;11:29. https://doi.org/10.1186/1476-511X-11-29.CrossRefPubMedPubMedCentral

102.

Asemi Z, Zare Z, Shakeri H, Sabihi S, Esmaillzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab. 2013;63:1–9. https://doi.org/10.1159/000349922.CrossRefPubMed

103.

Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a randomized placebo controlled trial. Diabetes Metab Syndr Clin Res Rev. 2019;13:175–82. https://doi.org/10.1016/j.dsx.2018.08.008.CrossRef

104.

Sheth M, Chand V, Thakuria A. Inflated levels of SCFA, Bifidobacteria and Lactobacillus improves the status of pre hypertension and type 2 diabetes mellitus in subjects residing in north East India–a randomized control trial with synbiotic supplementation. Int J Curr Pharm Res. 2015;7:33–6.

105.

Hachimura S, Totsuka M, Hosono A. Immunomodulation by food: impact on gut immunity and immune cell function. Biosci Biotechnol Biochem. 2018;82:584–99. https://doi.org/10.1080/09168451.2018.1433017.CrossRefPubMed

106.

Pedersen C, Gallagher E, Horton F, Ellis RJ, Ijaz UZ, Wu H, et al. Host–microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake. Br J Nutr. 2016;116:1869–77. https://doi.org/10.1017/S0007114516004086.CrossRefPubMed

107.

Canfora EE, van der Beek CM, Hermes GDA, Goossens GH, Jocken JWE, Holst JJ, et al. Supplementation of diet with galacto-oligosaccharides increases Bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. Gastroenterology. 2017;153:87–97.e3. https://doi.org/10.1053/j.gastro.2017.03.051.CrossRefPubMed

108.

Wang DD, Hu FB. Precision nutrition for prevention and management of type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6:416–26. https://doi.org/10.1016/S2213-8587(18)30037-8.CrossRefPubMed

Title: Diet, Microbioma, and Diabetes in Aging
Authors: Shirley Steffany Muñoz Fernandez
Sandra Maria Lima Ribeiro
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Insulins
Respiratory Microbiota
Insulins
Published in: Current Geriatrics Reports / Issue 4/2020
Electronic ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-020-00339-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Diet, Microbioma, and Diabetes in Aging

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2020

Mobility in Acute Care for Geriatric Patients with Orthopedic Conditions: a Review of Recent Literature

Melanoma Diagnosis and Treatment in the Elderly

Geriatric Vulvar Dermatology

Effect of Prehabilitation in Older Adults Undergoing Total Joint Replacement: an Overview of Systematic Reviews

Geriatric Orthopedics and Challenges with Mild Cognitive Impairment

Traditional Fermented Foods as an Adjuvant Treatment to Diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page